FDG-PET can be used to identify biomarkers for progression of mild cognitive impairment that occurs independently of the amyloid deposits commonly found with Alzheimer's disease (AD).
That's according to a study presented at this week's Joint Congress of European Neurology in Istanbul.
While a small portion of patients with mild cognitive impairment exhibit neurodegeneration without leading to amyloid deposits typical of AD, a team including co-author Dr. Philip Scheltens, PhD, from the Free University in Amsterdam found that FDG-PET was able to identify biomarker predictors for the prognosis of suspected non-AD pathophysiology, according to the Joint Congress of European Neurology.
